Literatur
- 1
Laing S P, Swerdlow A J, Slater S D et al.
Mortality from heart disease in a cohort of 23 000 patients with insulin-treated diabetes.
Diabetologia.
2003;
46
760-765
- 2
Laing S P, Swerdlow A J, Carpenter L M et al.
Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated
diabetes.
Stroke.
2003;
34
418-421
- 3
Laing S P, Swerdlow A J, Slater S D et al.
The British Diabetic Association Cohort Study, II: cause-specific mortality in patients
with insulin-treated diabetes mellitus.
Diabet Med.
1999;
16
466-471
- 4
UK Prospective Diabetes Study (UKPDS) Group .
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet.
1998;
352
837-853
- 5
Colwell J A, Nesto R W.
The platelet in diabetes: focus on prevention of ischemic events.
Diabetes Care.
2003;
26
2181-2188
- 6
Ageno W, Becattini C, Brighton T et al.
Cardiovascular risk factors and venous thromboembolism: a meta-analysis.
Circulation.
2008;
117
93-102
- 7
Tschoepe D.
The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes.
Semin Thromb Hemost.
1995;
21
152-160
- 8
Hilberg T, Eichler E, Glaser D et al.
Platelet activity, reactivity and platelet-leukocyte conjugate formation before and
after exhaustive or moderate exercise in patients with IDDM.
Platelets.
2004;
15
101-108
- 9
Hughes A, McVerry B A, Wilkinson L et al.
Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2
diabetic patients.
Acta Haematol.
1983;
69
254-259
- 10
Garcia Frade L J, de la Calle H, Alava I et al.
Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments
and vascular damage.
Thromb Res.
1987;
47
533-540
- 11
Watala C, Boncer M, Golanski J et al.
Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2
diabetes mellitus.
Eur J Haematol.
1998;
61
319-326
- 12
Halushka P V, Rogers R C, Loadholt C B et al.
Increased platelet prostaglandin and thromboxane synthesis in diabetes mellitus.
Horm Metab Res Suppl.
1981;
11
7-11
- 13
Tschoepe D, Rauch U, Schwippert B.
Platelet-leukocyte-cross-talk in diabetes mellitus.
Horm Metab Res.
1997;
29
631-635
- 14
Gawlowski T, Stratmann B, Ruetter R et al.
Advanced glycation end products strongly activate platelets.
Eur J Nutr.
2009;
48
475-481
- 15
Rubenstein D A, Yin W.
Glycated albumin modulates platelet susceptibility to flow induced activation and
aggregation.
Platelets.
2009;
20
206-215
- 16
Ferroni P, Basili S, Falco A et al.
Platelet activation in type 2 diabetes mellitus.
J Thromb Haemost.
2004;
2
1282-1291
- 17
Steering Committee of the Physicians’ Health Study Research Group .
Final report on the aspirin component of the ongoing Physicians’ Health Study.
N Engl J Med.
1989;
321
129-135
- 18
Ferreira I A, Mocking A I, Feijge M A et al.
Platelet inhibition by insulin is absent in type 2 diabetes mellitus.
Arterioscler Thromb Vasc Biol.
2006;
26
417-422
- 19
Balletshofer B M, Rittig K, Enderle M D et al.
Endothelial dysfunction is detectable in young normotensive first-degree relatives
of subjects with type 2 diabetes in association with insulin resistance.
Circulation.
2000;
101
1780-1784
- 20
Caballero A E, Arora S, Saouaf R et al.
Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2
diabetes.
Diabetes.
1999;
48
1856-1862
- 21
Vanhoutte P M.
Endothelial dysfunction: the first step toward coronary arteriosclerosis.
Circ J.
2009;
73
595-601
- 22
Bierhaus A, Illmer T, Kasper M et al.
Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured
endothelial cells is dependent on RAGE.
Circulation.
1997;
96
2262-2271
- 23
Basta G, Lazzerini G, Del Turco S et al.
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell
adhesion molecule-1 induction by advanced glycation end products.
Arterioscler Thromb Vasc Biol.
2005;
25
1401-1407
- 24
Esposito C, Gerlach H, Brett J et al.
Endothelial receptor-mediated binding of glucose-modified albumin is associated with
increased monolayer permeability and modulation of cell surface coagulant properties.
J Exp Med.
1989;
170
1387-1407
- 25
Hafer-Macko C E, Ivey F M, Gyure K A et al.
Thrombomodulin deficiency in human diabetic nerve microvasculature.
Diabetes.
2002;
51
1957-1963
- 26
Stratton I M, Adler A I, Neil H A et al.
Association of glycaemia with macrovascular and microvascular complications of type 2
diabetes (UKPDS 35): prospective observational study.
BMJ.
2000;
321
405-412
- 27
Gerstein H C, Riddle M C, Kendall D M et al.
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial.
Am J Cardiol.
2007;
99
34i-43i
- 28
Patel A, MacMahon S, Chalmers J et al.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
N Engl J Med.
2008;
358
2560-2572
- 29
Abraira C, Colwell J, Nuttall F et al.
Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility
Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in
Type II Diabetes.
Arch Intern Med.
1997;
157
181-188
- 30
Holman R R, Paul S K, Bethel M A et al.
10-year follow-up of intensive glucose control in type 2 diabetes.
N Engl J Med.
2008;
359
1577-1589
- 31
Carr M E.
Diabetes mellitus: a hypercoagulable state.
J Diabetes Complications.
2001;
15
44-54
- 32
Grant P J.
Diabetes mellitus as a prothrombotic condition.
J Intern Med.
2007;
262
157-172
- 33
Kantartzis K, Machann J, Schick F et al.
Effects of a lifestyle intervention in metabolically benign and malign obesity.
Diabetologia.
2010;
[Epub ahead of print]
- 34
Rittig K, Hieronimus A, Thamer C et al.
Reducing visceral adipose tissue mass is essential for improving endothelial function
in type 2 diabetes prone individuals.
Atherosclerosis.
2010;
212
575-579
- 35
Antithrombotic Trialists’ Collaboration .
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention
of death, myocardial infarction, and stroke in high risk patients.
BMJ.
2002;
324
71-86
- 36
Ajjan R, Storey R F, Grant P J.
Aspirin resistance and diabetes mellitus.
Diabetologia.
2008;
51
385-390
- 37
McKee S A, Sane D C, Deliargyris E N.
Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms,
and clinical significance.
Thromb Haemost.
2002;
88
711-715
- 38
Angiolillo D J, Fernandez-Ortiz A, Bernardo E et al.
Influence of aspirin resistance on platelet function profiles in patients on long-term
aspirin and clopidogrel after percutaneous coronary intervention.
Am J Cardiol.
2006;
97
38-43
- 39
Tantry U S, Bliden K P, Gurbel P A.
Overestimation of platelet aspirin resistance detection by thrombelastograph platelet
mapping and validation by conventional aggregometry using arachidonic acid stimula5tion.
J Am Coll Cardiol.
2005;
46
1705-1709
- 40
Catella-Lawson F, Reilly M P, Kapoor S C et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med.
2001;
345
1809-1817
- 41
Patrono C, Bachmann F, Baigent C et al.
Expert consensus document on the use of antiplatelet agents. The task force on the
use of antiplatelet agents in patients with atherosclerotic cardiovascular disease
of the European society of cardiology.
Eur Heart J.
2004;
25
166-181
- 42
Ryden L, Standl E, Bartnik M et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.
The Task Force on Diabetes and Cardiovascular Diseases of the European Society of
Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).
Eur Heart J.
2007;
28
88-136
- 43
Krasopoulos G, Brister S J, Beattie W S et al.
Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis.
BMJ.
2008;
336
195-198
- 44
Snoep J D, Hovens M M, Eikenboom J C et al.
Association of laboratory-defined aspirin resistance with a higher risk of recurrent
cardiovascular events: a systematic review and meta-analysis.
Arch Intern Med.
2007;
167
1593-1599
- 45
Erlinge D, Varenhorst C, Braun O O et al.
Patients with poor responsiveness to thienopyridine treatment or with diabetes have
lower levels of circulating active metabolite, but their platelets respond normally
to active metabolite added ex vivo.
J Am Coll Cardiol.
2008;
52
1968-1977
- 46
Angiolillo D J, Bernardo E, Capodanno D et al.
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus
patients with coronary artery disease taking dual antiplatelet therapy.
J Am Coll Cardiol.
2010;
55
1139-1146
- 47
Gaborit B, Frere C, Cuisset T et al.
Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently
related to plasma fibrinogen level but not to glycemic control.
J Thromb Haemost.
2009;
7
1939-1941
- 48
Pignone M, Alberts M J, Colwell J A et al.
Aspirin for primary prevention of cardiovascular events in people with diabetes: a
position statement of the American Diabetes Association, a scientific statement of
the American Heart Association, and an expert consensus document of the American College
of Cardiology Foundation.
Diabetes Care.
2010;
33
1395-1402
- 49
De Berardis G, Sacco M, Strippoli G F et al.
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis
of randomised controlled trials.
BMJ.
2009;
339
b4531
- 50
Nicolucci A, De Berardis G, Sacco M et al.
AHA / ADA vs. ESC / EASD recommendations on aspirin as a primary prevention strategy
in people with diabetes: how the same data generate divergent conclusions.
Eur Heart J.
2007;
28
1925-1927
- 51
Camm A J, Kirchhof P, Lip G Y et al.
Guidelines for the management of atrial fibrillation: the Task Force for the Management
of Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J.
2010;
31
2369-2429
- 52
Vieweg A, Standl E, Schnell O.
Orale Antikoagulation bei Diabetes und Vorhofflimmern.
Diabetes, Stoffwechsel und Herz.
2007;
16
179-182
- 53
Kannel W B, McGee D L.
Diabetes and cardiovascular disease. The Framingham study.
JAMA.
1979;
241
2035-2038
- 54
Haffner S M, Lehto S, Ronnemaa T et al.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic
subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
- 55
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) .
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III) final report.
Circulation.
2002;
106
3140-3141
- 56
Franklin K, Goldberg R J, Spencer F et al.
Implications of diabetes in patients with acute coronary syndromes. The Global Registry
of Acute Coronary Events.
Arch Intern Med.
2004;
164
1457-1463
- 57
Wiviott S D, Braunwald E, Angiolillo D J et al.
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel
in patients with diabetes mellitus in the trial to assess improvement in therapeutic
outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial
Infarction 38.
Circulation.
2008;
118
1626-1636
- 58
Schror K, Huber K.
[Prasugrel, a new thienopyridine].
Hamostaseologie.
2007;
27
351-355
- 59
Roffi M, Chew D P, Mukherjee D et al.
Platelet glycoprotein II b / III a inhibitors reduce mortality in diabetic patients
with non-ST-segment-elevation acute coronary syndromes.
Circulation.
2001;
104
2767-2771
- 60
Theroux P, Alexander Jr J, Pharand C et al.
Glycoprotein II b / III a receptor blockade improves outcomes in diabetic patients
presenting with unstable angina / non-ST-elevation myocardial infarction: results
from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients
Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.
Circulation.
2000;
102
2466-2472
- 61
Detre K M, Lombardero M S, Brooks M M et al.
The effect of previous coronary-artery bypass surgery on the prognosis of patients
with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization
Investigation Investigators.
N Engl J Med.
2000;
342
989-997
- 62
Banning A P, Westaby S, Morice M C et al.
Diabetic and nondiabetic patients with left main and / or 3-vessel coronary artery
disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
J Am Coll Cardiol.
2010;
55
1067-1075
- 63
Dauerman H L.
Percutaneous coronary intervention, diabetes mellitus, and death.
J Am Coll Cardiol.
2010;
55
1076-1079
- 64
Bertrand M E, Rupprecht H J, Urban P et al.
Double-blind study of the safety of clopidogrel with and without a loading dose in
combination with aspirin compared with ticlopidine in combination with aspirin after
coronary stenting : the clopidogrel aspirin stent international cooperative study
(CLASSICS).
Circulation.
2000;
102
624-629
- 65
Bhatt D L, Bertrand M E, Berger P B et al.
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel
after stenting.
J Am Coll Cardiol.
2002;
39
9-14
- 66
Demchuk A M, Morgenstern L B, Krieger D W et al.
Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral
hemorrhage in acute ischemic stroke.
Stroke.
1999;
30
34-39
- 67
Hacke W, Kaste M, Bluhmki E et al.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
N Engl J Med.
2008;
359
1317-1329
- 68
Adams R J, Albers G, Alberts M J et al.
Update to the AHA / ASA recommendations for the prevention of stroke in patients with
stroke and transient ischemic attack.
Stroke.
2008;
39
1647-1652
- 69
Albers G W, Amarenco P, Easton J D et al.
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of
Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Chest.
2008;
133
630S-669S
- 70
Weimar C, Goertler M, Rother J et al.
Systemic risk score evaluation in ischemic stroke patients (SCALA): a prospective
cross sectional study in 85 German stroke units.
J Neurol.
2007;
254
1562-1568
- 71 Diener H C, Allenberg J R, Bode C et al. Leitlinie Primär- und Sekundärprävention
der zerebralen Ischämie.. In: Kommission Leitlinien der Deutschen Gesellschaft für
Neurologie (DGN) und der Deutschen Schlaganfallgesellschaft (DSG), Hrsg. Leitlinien
für Diagnostik und Therapie in der Neurologie.. Stuttgart: Thieme; 2008
Dr. med. H.-G. Kopp
Abteilung für Onkologie, Hämatologie, klinische Immunologie, Rheumatologie und Pulmologie
· Medizinische Universitätsklinik Tübingen
Otfried Müller Straße 10
72076 Tübingen
eMail: hans-georg.kopp@med.uni-tuebingen.de
